Abstract 306P
Background
ALK gene rearrangement occurs in 3-7% of non-Sq-NSCLC. Tumor ALK testing by immunohistochemistry (IHC) is recommended. Next generation sequencing (NGS) and fluorescent-in-situ hybridization are validated for samples with inconclusive IHC staining. NGS testing of plasma ctDNA is non-invasive, allowing diagnosis where tissue is inaccessible, and detection of resistance mutations post-progression. One study has reported clinical utility of ALK testing using NGS on plasma, but data are otherwise limited to small samples. We assessed clinical utility of ctDNA NGS for ALK testing for non-Sq-NSCLC in Asia.
Methods
Between September 2015 to May 2020, 464 plasma specimens from 413 patients were analyzed. ctDNA was genotyped using Guardant360 (Guardant Health, Redwood City CA USA). Data on clinicopathologic features and treatment status were extracted from database (Sanomics Ltd, Hong Kong).
Results
ALK fusion and/or resistance mutations were detected in ctDNA of 24 (6%) non-Sq-NSCLC patients. 12 patients (50%) were male. 19 (79%) were adenocarcinoma, 5 (21%) were unknown. Tumor ALK status was available in 21 patients: 13 were ALK positive, 8 previously tested negative. ALK fusion partners included EML4 (85.7%), STRN (9.5%), and KIF5B (4.8%). ALK resistance mutations were detected only in patients with prior ALK inhibitor treatment (8/12, 67%). 13 types of resistance mutations were identified: G1202R, then L1196M, were the most frequent. (Table) Table: 306P
Patient no. | 1a | 1b | 2a | 2b | 3a | 3b | 3c | 4a | 4b | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | |
Prior TKI treatment | NA | Y | NA | NA | Y | Y | Y | O | O | NA | O | Y | Y | Y | N | Y | N | Y | Y | Y | O | Y | NA | Y | O | Y | NA | O | O | |
ALK TKI | Crizotinib | Y | Y | Y | Y | Y | NA | |||||||||||||||||||||||
Ceritinib | Y | Y | Y | |||||||||||||||||||||||||||
Alectinib | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | ||||||||||||||||||||
Lorlatinib | Y | Y | Y | |||||||||||||||||||||||||||
ALK fusion | EML4-ALK | P | P | P | P | P | P | P | P | P | P | P | P | P | P | P | P | P | P | P | ||||||||||
KIF5B-ALK | P | |||||||||||||||||||||||||||||
STRN-ALK | P | P | ||||||||||||||||||||||||||||
ALK resistance mutation | E1210K | P | ||||||||||||||||||||||||||||
D1203N | P | |||||||||||||||||||||||||||||
F1174C | P | |||||||||||||||||||||||||||||
F1174L | P | P | P | |||||||||||||||||||||||||||
G1202R | P | P | P | P | P | |||||||||||||||||||||||||
G1269A | P | |||||||||||||||||||||||||||||
I1171N | P | |||||||||||||||||||||||||||||
I1171T | P | P | ||||||||||||||||||||||||||||
L1152R | P | |||||||||||||||||||||||||||||
L1196M | P | P | P | P | ||||||||||||||||||||||||||
L1196Q | P | |||||||||||||||||||||||||||||
L1198F | P | P | ||||||||||||||||||||||||||||
V1180L | P | P |
NOTE: TKI - tyrosine kinase inhibitor; a, b, c - 1st, 2nd, 3rd ctDNA NGS test; NA - not available; Y - yes; N - no; O - other therapy; P - positive.
Conclusions
NGS testing for ALK fusions and genomic alterations in plasma ctDNA has clinical utility in non-Sq-NSCLC patients in guiding ALK targeted treatment at initial diagnosis and upon cancer progression. Detection rate and distribution of ALK fusion partners are comparable to existing data of tumor ALK testing. Further data on ALK treatment outcomes of patients with detectable ALK fusion on plasma ctDNA is warranted.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sanomics Limited.
Funding
Has not received any funding.
Disclosure
K.W.C. Lee, S.T. Wu, P.Y. Lo, C.T. Choy, T.C. Kwong, Y.T.N. Lau. L. Lin, S.W. Lau: Full/Part-time employment: Sanomics Limited.
Resources from the same session
67TiP - HER2CLIMB-02: A randomized, double-blind, phase III study of tucatinib or placebo with T-DM1 for unresectable locally-advanced or metastatic HER2+ breast cancer
Presenter: Norikazu Masuda
Session: e-Poster Display Session
68TiP - KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) + olaparib (ola) vs pembro + chemotherapy after induction with first-line (1L) pembro + chemo in patients (pts) with locally recurrent inoperable or metastatic TNBC
Presenter: Shigehira Saji
Session: e-Poster Display Session
69TiP - MADELINE Asia: A mobile app-based prospective observational study of patient reported outcomes in advanced breast cancer in Asia
Presenter: Anna Tai
Session: e-Poster Display Session
113TiP - Prospective observational study monitoring circulating tumour DNA in resectable colorectal cancer patients undergoing radical surgery: GALAXY study in CIRCULATE-Japan
Presenter: Hiroki Yukami
Session: e-Poster Display Session
195TiP - GLOW: Phase III study of first-line zolbetuximab + CAPOX versus placebo + CAPOX in Claudin18.2⁺/HER2⁻ advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)
Presenter: Rui-Hua Xu
Session: e-Poster Display Session
196TiP - Perioperative sintilimab in combination with concurrent chemoradiotherapy for patients with locally advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma
Presenter: Jia Wei
Session: e-Poster Display Session
197TiP - A randomized, double-blind, phase III study of pembrolizumab plus chemotherapy as first-line therapy in patients with HER2-negative, advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: KEYNOTE-859
Presenter: Shukui Qin
Session: e-Poster Display Session
198TiP - SPOTLIGHT: Phase III study of zolbetuximab + mFOLFOX6 versus placebo + mFOLFOX6 in first-line Claudin18.2⁺/HER2⁻ advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)
Presenter: Kohei Shitara
Session: e-Poster Display Session
233TiP - Pembrolizumab (pembro) or placebo added to docetaxel and prednisone/prednisolone for metastatic castration-resistant prostate cancer (mCRPC) previously treated with next-generation hormonal agents (NHAs): KEYNOTE-921 phase III study
Presenter: Daniel Petrylak
Session: e-Poster Display Session
254TiP - ENGOT-cx11/KEYNOTE-A18: A Phase 3, Randomized, Double-Blind Study of Pembrolizumab With Chemoradiotherapy in Patients With High-Risk Locally Advanced Cervical Cancer
Presenter: Domenica Lorusso
Session: e-Poster Display Session